Comparison between the efficacy and tolerability of On Demand Sildenafil citrate and Tadalafil in Treatment of Erectile Dysfunction in Type 2 Diabetic Patients
Abstract
Introduction: Data from head-to-head clinical trials of phosphodiesterase type 5 inhibitors are scarce, making it difficult for clinicians to select the most appropriate treatment for their patients with erectile dysfunction.
Aim: To compare efficacy and tolerability of Sildenafil and Tadalafil in men with erectile dysfunction and diabetes.
Method: A clinical, crossover and open label study was used.
A group of 95 patients were randomly recruited and answered an adapted questionnaire before and after usage of Sildenafil 100 mg and Tadalafil 20 mg to determine the improvement and compare efficacy and tolerability of each drug.
RESULTS: The one tailed Wilcoxon signed-rank test results for all the questions suggest that there is no statistically significant difference in response between Tadalafil and sildenafil p >0.05. However, for erection maintenance ability after penetration and for the overall response, the results suggest that there are statistically significant differences in response between Tadalafil and sildenafil p <0.05 in favor of Tadalafil.
Conclusion: Both drugs were highly effective and well tolerated in diabetic patients. Patient’s score on the erection scale with Tadalafil was superior than sildenafil in all questions. However, statistically significant differences were only detected in maintenance ability after penetration and the overall response. Probably, more significance could be detected if the sample size was larger.
